ArticlePloS one2026
Virological failure and risk factors among people living with HIV taking second-line ART in Addis Ababa, Ethiopia.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVirological failure (VF) presents significant challenges in the emergence of drug resistance, and elevated risk of transmission, higher mortality rates, and a diminished quality of life. Various factors contribute to VF, but documented information on this issue is lacking in Ethiopia. Therefore, this study aimed to assess the prevalence of VF and identify the risk factors among people living with HIV who are on second-line antiretroviral treatment (ART).
methodsA concurrent mixed-method study using quantitative and qualitative data was conducted at selected hospitals in Addis Ababa, Ethiopia. The analysis was conducted using SPSS version 28, Stata version 18.5, and R for quantitative data and thematic analysis with Atlas.ti version 24 software was used for qualitative data.
resultAmong 369 adults living with HIV taking second-line ART enrolled in the study, 191 (52%) were male with a median age of 44 years. The prevalence of VF was 55 (14.9%, 95% CI: 11, 19), with an incidence density of 27.2 per 10,000 person months (95% CI 21.1, 35.5). Lost to follow-up significantly increased VF risk [AHR: 2.52 (95% CI: 1.35, 4.69, p-value: 0.004)]. Patients transferred from other health facilities were two times at higher risk of VF compared to those receiving ART at the same facility [AHR: 1.97 (95% CI: 1.07, 3-64, p-value: 0.029)]. Likewise, clients with a history of regimen change were at a higher risk of VF [AHR = 2.05, (95% CI: 1.08, 3.88, p-value = 0.027)]. The qualitative data also supported these findings.
conclusionThis study underscores the need for improved ART adherence and consistent care to reduce virological failure in PLHIV to improve the quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.